Race Oncology Limited (“Race”) is pleased to provide shareholders with a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential.

Key highlights:

• New corporate strategy launched, detailing Race’s optimised clinical program and key areas of discovery, placing Race at the heart of cancer care
• Lead clinical focus on investigating anti-cancer, plus cardio-protective and FTO properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer
• Secondary focus on pursuing increased anti-cancer / FTO benefits of bisantrene combined with current standard of care therapies in acute myeloid leukaemia (AML)
• Targeted R&D program designed to maximise bisantrene’s partnering potential
• Video update, presentation and shareholder information sessions available to provide additional background and offer Q+A opportunities      
• Investors are also invited to visit the Interactive Announcements page in Race’s Investor Hub to submit questions https://announcements.raceoncology.com

Read the strategic update summary and investor presentation here.

Non-Executive Chair, Mary Harney commented: “Through the course of conducting this review of strategy, Race drew upon a rich set of insights. We further reviewed our deep historic clinical dataset, as well as many preclinical studies across a range of indications. We investigated the many market opportunities for bisantrene and engaged with key opinion leaders to inform our view of unmet patient need. Finally, and of critical importance, we reviewed the paths to market which would position our lead asset most strongly with potential partners.

This strategic update delivers committed and planned programs, designed to optimally leverage bisantrene RC220’s potential in the areas of anti-cancer, cardio-protection and FTO inhibition. This has been a significant body of work – I thank the Race team for their dedication in driving toward the best outcome and am also grateful for the ongoing interest and support of our shareholders.”

Race CEO and Managing Director, Damian Clarke-Bruce commented: “Race’s revised development program has been designed in such a way that our new bisantrene formulation can fit straight into a global pharmaceutical partner’s pipeline. Through our rigorous clinical development plan, Race will investigate bisantrene RC220 in both metastatic breast cancer and continue our clinical experience in AML, while investigating and expanding our knowledge of its mechanism of action. We have a clear regulatory pathway and a program that is supported by international key opinion leaders, for a drug candidate which has already been shown to improve patients’ lives.

We look forward to presenting the strategy to existing and potential new shareholders over the coming weeks as we seek to advance our position as a commercial partner with a life-changing therapeutic asset in bisantrene RC220.”

Investors are invited to view a copy of the video presentation below.

(1) Fat mass and obesity associated protein